Ortensia A, Delle Volpe M, Iberti M, Veronesi G V, De Micheli G
U.S.S.L. n. 70, Ospedale Civile, Alessandria, Divisione di Nefrologia e Dialisi.
Minerva Urol Nefrol. 1990 Jan-Mar;42(1):51-3.
Pharmacological treatment with urokinase in obstructions of vascular accesses due to chronic dialysis is a tried and tested technique. Retrospective investigation of a group of 111 cases treated with urokinase makes it possible to calculate the actuarial survival curve of vascular access in the period subsequent to fibrinolytic treatment. Mathematical analysis provides a precise indication to the use of the drug in thromboses of a-v fistulas and anatomically unimpaired vascular prothesies. In the presence of stenosis of a-v anastomosis, pharmacological thrombolysis permits restoration of a blood flow suitable to the conduction of haemodialytic treatment for a period useful to surgical correction. Infusion of urokinase is useless in cases of vascular prosthesis thrombosis complicated by the presence of stenosis of the lumen.
用尿激酶对慢性透析所致血管通路阻塞进行药物治疗是一种经过验证的技术。对一组111例接受尿激酶治疗的病例进行回顾性研究,使得能够计算出纤维蛋白溶解治疗后血管通路的精算生存曲线。数学分析为尿激酶在动静脉内瘘血栓形成及解剖结构未受损的血管假体中的应用提供了精确指导。在动静脉吻合口狭窄的情况下,药物溶栓可在一段有利于手术矫正的时间内恢复适合进行血液透析治疗的血流。对于伴有管腔狭窄的血管假体血栓形成病例,输注尿激酶是无效的。